Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
08/2003
08/07/2003WO2003046556A3 Globin biopolymer markers indicative of insulin resistance
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149256 Transferrin polynucleotides, polypeptides, and antibodies
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149107 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149071 Pyrido [2,1-a] isoquinoline derivatives
08/07/2003US20030149067 Crystallisation of the desired crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149040 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149026 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc.
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148941 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
08/07/2003US20030148938 Aqueous sustained-release formulations of proteins
08/07/2003US20030148516 Medium containing flt3 ligand for culturing hematophoietic cells
08/07/2003US20030148515 Generating blood producing tissues from central nervous system pluripotent cells for repair, regeneration or augmentation of mammalian hematopoietic system; gene therapy; tissue engineering; blood disorders; anticarcinogenic agents
08/07/2003US20030148512 Preparing culture of vascular system progenitor cells for tissue engineering and treatment of vascular disorders
08/07/2003US20030148327 Nucleic acid of given sequence; oligonucleotides and oligomers for detecting the cytosine methylation of genes; tumors and cancer
08/07/2003US20030148326 Diagnosis of diseases associated with dna transcription
08/07/2003US20030148323 Analyzing nucleic acid and determining presence of mutant alleles encoding a protein with reduced activity/thermal stability; useful in diagnosing schizophrenia
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003US20030147853 Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
08/07/2003CA2474788A1 Compositions and methods for modulating connexin hemichannels
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473797A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003CA2473457A1 Cotherapy with an oxazolidinone and a vitamin b
08/07/2003CA2473169A1 Compounds that inhibit factor xa activity
08/07/2003CA2473164A1 Novel compounds that inhibit factor xa activity
08/06/2003EP1333036A1 Peg-modified erythropoietin
08/06/2003EP1332218A1 Differentiation-inducing substances
08/06/2003EP1332159A1 Process for the preparation of latent antithrombin iii
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332129A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1331977A1 Blood centrifuge cup having a replaceable compartment for filter support
08/06/2003EP1331950A1 Methods and compositions for nucleic acid delivery
08/06/2003EP1331944A1 Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1189929B1 Factor viia inhibitors
08/06/2003EP1176149B1 Novel gymnemic acid derivatives, process for the preparation thereof and use thereof as medicine
08/06/2003EP1165544B1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
08/06/2003EP0804465B1 Novel elastase inhibitors
08/06/2003CN1434825A Novel imidazo ÒÇö1,3,5ÒÇòtriazinones and the use thereof
08/06/2003CN1434822A Substituted oxazolidinones and their use in the field of blood coagulation
08/06/2003CN1434801A Substited 8-anylquinoline phosphodiesterase-4 inhibitors
08/06/2003CN1434797A Hydrazone and oxime derivatives of pyrrolidine as AMP-specific phosphodiesterase inhibitons
08/06/2003CN1434795A Acyl pseudodipeptides which carry a functionalised auxiliary arm
08/06/2003CN1434794A Adamantane derivatives
08/06/2003CN1434727A Anglogenesis and vascular permeability modulators and inhibitors
08/06/2003CN1434726A Multivalent platform molecules comprising high molecular weight polyethylene oxide
08/06/2003CN1434722A Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
08/06/2003CN1434721A Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy
08/06/2003CN1434720A Medicinal compositions for treating and preventing diseases based on abnormal blood coagulation
08/06/2003CN1434719A Preparation capable of mobilization of activity
08/06/2003CN1434712A Nitrosated and nitrosylated cyclooxygenase-2 inhibitors compositions and methods of use
08/06/2003CN1434119A Establishment and use of adult stem cell restitution hemopoiesis method of mesenchyme stem cell phynotype
08/06/2003CN1434055A Platelet glucoprotein receptor inhibitor, medicinal composition containing same and use thereof
08/06/2003CN1433789A Health care adhesive plaster capable of accelerating blood circulation and discharging toxicity
08/06/2003CN1433779A Process for preparing snake venom hemostatic medicine
08/06/2003CN1433712A Technological process for preparing beverage, oral liquor electuar, and antitoxic tablet from fern root
08/06/2003CN1117092C Azadicyclic compound, its medicinal composition and medicinal use
08/06/2003CN1117089C Substituted 2(2,6-dioxopiperidin-3-yl)phthaliomides and -1-xoisoindolines and method of reducing TNF-alpha levels
08/06/2003CN1117082C Substituted imidazoles having anti-cancer and cytokine inhibitory activity
08/06/2003CN1117077C 6-phenylpyridyl-2-amine derivatives useful asNOS inhibitors
08/05/2003US6603008 Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
08/05/2003US6602881 Anti-inflammatory uses of manzamines
08/05/2003US6602876 Adhesion receptor antagonists
08/05/2003US6602872 Substituted pyridazines having cytokine inhibitory activity
08/05/2003US6602871 Thrombin or factor Xa inhibitors
08/05/2003US6602864 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
08/05/2003US6602503 Complementarity determining regions (CDRs); asthma and inflammatory bowel disease; integrins; antigen binding regions derived from the heavy and/ or light chain variable regions
08/05/2003US6602274 Targeted transcutaneous cancer therapy
08/05/2003CA2079374C (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
07/2003
07/31/2003WO2003062392A2 Methods of treating conditions associated with an edg receptor
07/31/2003WO2003062279A1 Nutraceuticals for the treatment, protection and restoration of connective tissues
07/31/2003WO2003062276A2 Multimers of receptor-binding ligands
07/31/2003WO2003062275A1 Glycoisoforms of adiponectin and uses thereof
07/31/2003WO2003062252A1 Edg receptor agonists
07/31/2003WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
07/31/2003WO2003062240A1 Pteridine derivatives, method for the production thereof, and use thereof
07/31/2003WO2003062233A1 2-acylaminothiazole derivative or salt thereof
07/31/2003WO2003062227A1 Rho-kinase inhibitors
07/31/2003WO2003062225A1 Pyrimidine derivatives as rho-kinase inhibitors
07/31/2003WO2003062206A2 Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
1 ... 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 ... 671